Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Covington
QuintilesIMS
Johnson and Johnson
Chubb
Express Scripts
Fuji
Dow
Cerilliant
Daiichi Sankyo

Generated: February 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,471,025

« Back to Dashboard

Which drugs does patent 8,471,025 protect, and when does it expire?

Patent 8,471,025 protects AVYCAZ and is included in one NDA.

This patent has twenty patent family members in twelve countries.
Summary for Patent: 8,471,025
Title:Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt
Abstract: The present invention relates to novel crystalline forms of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) thereof. The present invention relates to compositions comprising a crystalline form of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil). Processes for the preparation of the crystalline forms and methods of treating bacterial infections by administering the crystalline forms alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil) are also described.
Inventor(s): Dedhiya; Mahendra G. (Pomona, NY), Bhattacharya; Sisir (Hauppauge, NY), Ducandas; Veronique (Vitry sur Seine, FR), Giuliani; Alexandre (Villecresnes, FR), Ravaux; Valerie (Reyrieux, FR), Bonnet; Alain (Chateau-Thierry, FR), Priour; Alain (Paris, FR), Spargo; Peter Lionel (Deal, GB)
Assignee:
Application Number:12/900,567
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 8,471,025

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan Sales Llc AVYCAZ avibactam sodium; ceftazidime POWDER;IV (INFUSION) 206494-001 Feb 25, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,471,025

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,835,455 Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt ➤ Sign Up
9,062,053 Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-Diazabicyclo[3,2,1]octane-2-carboxamide sodium salt ➤ Sign Up
9,580,424 Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,471,025

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation 2012118247 ➤ Sign Up
Mexico 2012003730 ➤ Sign Up
South Korea 20170134791 ➤ Sign Up
South Korea 20120106720 ➤ Sign Up
Japan 2017149754 ➤ Sign Up
Japan 6197170 ➤ Sign Up
Japan 2016029082 ➤ Sign Up
Japan 6072540 ➤ Sign Up
Japan 2013507346 ➤ Sign Up
Israel 239663 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Chinese Patent Office
Accenture
Teva
Federal Trade Commission
US Army
Citi
Dow
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot